Abstract
The purpose of this study was to compare the combination treatments of manidipine/delapril and olmesartan/hydrochlorothiazide (HCTZ) in elderly diabetic hypertensives. After a 4-week placebo period, 158 hypertensive patients with type 2 diabetes (age range: 66 to 74 years) were randomized to receive combination treatment of 10 mg manidipine plus 30 mg delapril or 20 mg olmesartan plus 12.5 mg HCTZ for 48 weeks in a prospective, parallel arm trial. After 12 weeks, manidipine or HCTZ was doubled in nonresponders (systolic blood pressure [SBP] ≥130 mmHg and/or diastolic blood pressure [DBP] ≥80 mmHg). Patients were checked at the end of the placebo period and every 12 weeks thereafter. At each visit, lying, sitting and standing BP as well as fasting glycemia, glycosylated hemoglobin (HbA1c), electrolytes, uric acid, total cholesterol (TC), high-density lipoprotein-cholesterol (HDL-C) and triglycerides (TG) were evaluated. Both combinations reduced sitting SBP (−27.7 and −28.3 mmHg, respectively; both p<0.001) and DBP (−15.1 and −14.8 mmHg, respectively; both p<0.01) with no difference between the two treatments. Standing DBP was more markedly reduced by olmesartan/HCTZ (−19.5 mmHg; p<0.001) than by manidipine/delapril (−14.7 mmHg; p<0.05 vs. olmesartan/HCTZ). No changes in metabolic parameters were observed with manidipine/delapril, whereas an increase in HbA1c (+0.7%; p<0.05), uric acid (+0.4 mg/dL; p<0.05) and TG (+41.3 mg/dL; p<0.05), and a decrease in serum potassium (−0.3 mmol/L; p<0.05) and HDL-C (−3.4 mg/dL; p<0.05) were found in the olmesartan/HCTZ group. In conclusion, both combinations were similarly effective in reducing BP in elderly hypertensive diabetic patients. However, manidipine/delapril offered some advantages in terms of the less-pronounced BP orthostatic changes and absence of metabolic adverse effects. (Hypertens Res 2008; 31: 43−50)
Similar content being viewed by others
Article PDF
References
European Society of Hypertension−European Society of Cardiology Guidelines Committee : 2003 guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011–1053.
Chobanian AV, Bakris GL, Black HR, et al : The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and treatment of High Blood Pressure. The JNC 7 Report. JAMA 2003; 289: 2560–2572.
UK Prospective Diabetes Study Group : Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703–713.
Hansson L, Zanchetti A, Carruthers SG, et al : Effects of intensive blood pressure lowering and low dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1998; 351: 1755–1762.
JATOS Study Group : The Japanese Trial to Assess Optimal Systolic Blood Pressure in Elderly Hypertensive Patients (JATOS): protocol, patient characteristics and blood pressure during the first 12 months. Hypertens Res 2005; 28: 513–520.
Sowers JR : Recommendations for special populations: diabetes mellitus and the metabolic syndrome. Am J Hypertens 2003; 16: 41S–45S.
Ichihara A, Hatashi M, Hirota N, et al : Angiotensin II type 2 receptor inhibits prorenin processing in juxtaglomerular cells. Hypertens Res 2003; 26: 915–921.
Heart Outcomes Prevention Evaluation Study Investigators : Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253–259.
Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P : The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870–878.
Saruta T, Nishikawa K : Characteristics of a new angiotensin converting enzyme inhibitor: delapril. Am J Hypertens 1991; 4: 23S–28S.
Cheer SM, McClellan K : Manidipine: a review of its use in hypertension. Drugs 2001; 61: 1777–1799.
Toba H, Shimizu T, Miki S, et al : Calcium channel blockers reduce angiotensin II−induced superoxide generation and inhibit lectin-like oxidized low-density lipoprotein receptor-1 expression in endothelial cells. Hypertens Res 2006; 29: 105–116.
Fogari R, Zoppi A, Lusardi P, et al : Evaluation by 24-hour ambulatory blood pressure monitoring of efficacy of manidipine hydrochloride 10, 20 or 40 mg once daily as compared to placebo in treating mild to moderate essential hypertension: a double-blind, randomized, parallel group, placebo-controlled study. Blood Press Suppl 1996; 5: 16–23.
Fogari R, Zoppi A, Mugellini A, et al : Efficacy of delapril in the treatment of mild to moderate essential hypertension: evaluation by 24-hour ambulatory blood pressure monitoring. Adv Ther 1997; 14: 254–261.
Mancia G, Omboni S, Agabiti-Rosei E, et al : Antihypertensive efficacy of manidipine and enalapril in hypertensive diabetic patients. J Cardiovasc Pharmacol 2000; 35: 926–931.
Omboni S, Fogari R, Mancia G : A smooth blood pressure control is obtained over 24 h by delapril in mild to moderate essential hypertensives. Blood Press 2001; 10: 170–175.
Hatta T, Nakata T, Harada S, et al : Lowering of blood pressure improves endothelial dysfunction by increase of nitric oxide production in hypertensive rats. Hypertens Res 2002; 25: 455–460.
Mugellini A, Dobovisek J, Planinc D, Cremonesi G, Fogari R : Efficacy and safety of delapril plus manidipine compared with enalapril plus hydrochlorothiazide in mild to moderate essential hypertension: results of a randomized trial. Clin Ther 2004; 26: 1419–1426.
Mugellini A, Vaccarella A, Celentano A, Scanferla F, Zoppi A, Fogari R : Fixed combination of manidipine and delapril in the treatment of mild to moderate essential hypertension: evaluation by 24-hour ambulatory blood pressure monitoring. Blood Press Suppl 2005; 1: 6–13.
Mizuno M, Sada T, Ikeda M, et al : Pharmacology of CS-866, a novel nonpeptide angiotensin II receptor antagonist. Eur J Pharmacol 1995; 285: 181–188.
Agata J, Ura N, Yoshida H, et al : Olmesartan is an angiotensin II receptor blocker with an inhibitory effect on angiotensin converting enzyme. Hypertens Res 2006; 29: 865–874.
Stumpe KO, Ludwig M : Antihypertensive efficacy of olmesartan compared with other antihypertensive drugs. J Hum Hypertens 2002; 16 ( Suppl 2): S24–S28.
Imai E, Haneda M, Chan JCN, Makino H, for the ORIENT Investigators : Olmesartan Reducing Incidence of Endstage Renal Disease in Diabetic Nephropathy Trial (ORIENT): rationale and study design. Hypertens Res 2006; 29: 703–709.
Sellin L, Stegbauer J, Laeis P, Rump LC : Adding hydrochlorothiazide to olmesartan dose dependently improves 24-h blood pressure and response rates in mild-to-moderate hypertension. J Hypertens 2005; 23: 2083–2092.
Rump LC, Ambrosioni E, Burnier M, Horl W, Rabelink AJ : Initial combination therapy with olmesartan/hydrochlorothiazide in moderate-to-severe hypertension. J Hum Hypertens 2006; 20: 299–301.
Maser RE, Lenhard MJ : Cardiovascular autonomic neuropathy due to diabetes mellitus: clinical manifestations, consequences, and treatment. J Clin Endocrinol Metab 2005; 90: 5896–5903.
Turnheim K : Drug therapy in the elderly. Exp Gerontol 2004; 39: 1731–1738.
Moriguchi K, Rakugi H, Nakata S, et al : Impairment of instantaneous autonomic regulation relates to blood pressure fall immediately after standing in the elderly and hypertensives. Hypertens Res 2006; 29: 557–566.
WHO Expert Committee on Diabetes Mellitus : second report. World Health Organ Tech Rep Ser 1980; 646: 1–80.
Expert Committee on the Diagnosis and Classification of Diabetes Mellitus : Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003; 26: S5–S20.
European Diabetes Policy Group : A desktop guide to type 2 diabetes mellitus. Diabet Med 1999; 16: 716–730.
Bunn HF, Gabbay KH, Gallop PM : The glycosylation of haemoglobin. Relevance to diabetes mellitus. Science 1978; 200: 21–27.
Klose S, Borner K : Enzymatische Bestimmung des Gesamtcholesterins mit dem [Enzymatic dosage of total cholesterolemia by Greiner Selective Analyzer (GSA II)]. J Clin Chem Clin Biochem 1978; 15: 121–130.
Wahlefeld AW : Triglycerides determination after enzymatic hydrolysis, in Bergmeyer HU, ( ed ): Methods of Enzymatic Analysis, 2nd English ed. New York, Academic Press, 1974, pp 18–31.
Havel RJ, Eder HA, Bragdon JH : The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 1955; 34: 1345–1353.
Friedewald WT, Levy RI, Fredrickson DS : Estimation of the concentration of low density lipoprotein in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499–502.
Masaki KH, Schatz IJ, Burchfiel CM, et al : Orthostatic hypotension predicts mortality in elderly men. The Honolulu Heart Program. Circulation 1998; 98: 2290–2295.
Rutan GH, Hermanson B, Bild DE, et al : Orthostatic hypotension in older adults: the Cardiovascular Health Study. Hypertension 1992; 19: 508–519.
Wu JS, Lu FH, Yang YC, et al : Postural hypotension and postural dizziness in patients with non-insulin dependent diabetes. Arch Intern Med 1999; 159: 1350–1356.
Christlieb AR, Munichoodappa C, Braaten JT : Decreased response of plasma renin activity to orthostasis in diabetic patients with orthostatic hypotension. Diabetes 1974; 23: 835–841.
Mathias CJ, Kimber JR : Postural hypotension: causes, clinical features, investigation and management. Annu Rev Med 1999; 50: 317–336.
The Consensus Committee of the American Autonomic Society and the American Academy of Neurology : Consensus statement on the definition of orthostatic hypotension, pure autonomic failure and multiple system atrophy. Neurology 1996; 46: 1470.
Wilson IM, Freis ED : Relationship between plasma and extracellular fluid volume depletion and the antihypertensive effects of chlorothiazide. Circulation 1959; 20: 1028–1036.
Puschett JB : Diuretics, in Oparil S, Weber MA, ( eds ): Hypertension: A Companion to Brenner and Rector's the Kidney. WB Saunders Company, Philadelphia 2000, pp 584–590.
Clayton JA, Rodgers S, Blakey J, Avery A, Hall IP : Thiazide diuretic prescription and electrolyte abnormalities in primary care. Br J Clin Pharmacol 2005; 61: 87–95.
Lithell HO : Effect of antihypertensive drugs on insulin, glucose and lipid metabolism. Diabetes Care 1991; 14: 203–209.
Elliot W : Glucose and cholesterol elevations during thiazide therapy: intention to treat versus actual on-therapy experience. Am J Med 1995; 99: 216–219.
Wilcox CS : Metabolic and adverse effects of diuretics. Semin Nephrol 1999; 19: 557–568.
Inaba M, Noguchi Y, Yamamoto T, et al : Effects of a low dose of indapamide, a diuretic, given daily or every-other-day on blood pressure and metabolic parameters. Hypertens Res 2004; 27: 141–145.
Fukuda M, Kimura G : Pathophysiology of antihypertensive therapy with diuretics. Hypertens Res 2006; 29: 645–653.
Kjeldsen SE, Os I, Hoieggen A, Beckey K, Gilbert GW, Oparil S : Fixed-dose combinations in the management of hypertension. Defining the place of angiotensin receptor antagonists and hydrochlorothiazide. Am J Cardiovasc Drugs 2005; 5: 17–22.
Palatini P : Combination therapy in the management of hypertension: focus on angiotensin receptor blockers combined with diuretics. J Clin Invest 2005; 7: 96–101.
Julius PS, Kjeldsen PS, Weber PM, et al : Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022–2031.
Suzuki S, Ohtomo M, Satoh Y, et al : Effect of manidipine and delapril on insulin sensitivity in type 2 diabetic patients with essential hypertension. Diabetes Res Clin Pract 1996; 33: 43–51.
Mugellini A, Preti P, Zoppi A, et al : Effect of delapril-manidipine combination vs irbesartan-hydrochlorothiazide combination on fibrinolytic function in hypertensive patients with type II diabetes mellitus. J Hum Hypertens 2004; 18: 687–691.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Fogari, R., Derosa, G., Zoppi, A. et al. Effects of Manidipine/Delapril versus Olmesartan/Hydrochlorothiazide Combination Therapy in Elderly Hypertensive Patients with Type 2 Diabetes Mellitus. Hypertens Res 31, 43–50 (2008). https://doi.org/10.1291/hypres.31.43
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1291/hypres.31.43
Keywords
This article is cited by
-
Thiazide Diuretic–Induced Change in Fasting Plasma Glucose: a Meta-analysis of Randomized Clinical Trials
Journal of General Internal Medicine (2020)
-
The benefits of angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers combined with calcium channel blockers on metabolic, renal, and cardiovascular outcomes in hypertensive patients: a meta-analysis
International Urology and Nephrology (2018)
-
RETRACTED ARTICLE: Different Aspects of Sartan + Calcium Antagonist Association Compared to the Single Therapy on Inflammation and Metabolic Parameters in Hypertensive Patients
Inflammation (2014)
-
Olmesartan in the Treatment of Hypertension in Elderly Patients: a Review of the Primary Evidence
Drugs & Aging (2013)
-
Comparative effect of olmesartan and candesartan on lipid metabolism and renal function in patients with hypertension: a retrospective observational study
Cardiovascular Diabetology (2011)